Coronary Artery DiseaseNCT07420582
Antegrade Autologous Blood Reinfusion After CPB
An observational study of Coronary Artery Disease, run by Kocaeli City Hospital at 1 site in Turkey (Türkiye).
Trial summary
This prospective observational study aims to evaluate the effect of antegrade pump blood reinfusion using the crystalloid "chase" technique on postoperative transfusion requirements in adult patients undergoing cardiac surgery with cardiopulmonary bypass. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Coronary Artery Disease
- What is being tested?
- Antegrade Pump Blood Reinfusion and No Anterograde Pump Blood Reinfusion
- Type of treatment
- Surgery or procedure
- How many people
- 130 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 23 Feb 2026to 18 Aug 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population includes adult patients (18-80 years) scheduled for elective, primary isolated coronary artery bypass grafting (CABG) using cardiopulmonary bypass at Kocaeli City Hospital.
Who may be able to join
- Age 18 to 80 years
- Patients undergoing elective, isolated coronary artery bypass grafting surgery using cardiopulmonary bypass (on-pump).
Who cannot join
- Emergency or Redo cardiac surgery
- Concomitant cardiac procedures (e.g., valve repair/replacement or aortic surgery).
- Planned or intraoperative conversion to off-pump coronary artery bypass grafting
- Preoperative hematocrit <30% or known inherited/acquired bleeding disorders.
- Preoperative left ventricular ejection fraction <30%.
- Thrombocytopenia (e.g., platelet count <100×10³/µL) or abnormal coagulation tests.
Show all 14Show fewer
- Use of antiplatelet agents other than aspirin without appropriate discontinuation according to current guideline-recommended preoperative intervals.
- Use of anticoagulant therapy without appropriate preoperative discontinuation according to current guideline recommendations.
- Use of any intraoperative allogeneic blood product (red blood cells, fresh frozen plasma, or platelets)
- Use of non-steroidal anti-inflammatory drugs (NSAIDs) without appropriate discontinuation prior to surgery.
- Severe renal dysfunction (eGFR <30 mL/min/1.73 m² or dialysis) and/or severe hepatic dysfunction (Child-Pugh B-C or coagulopathy).
- Active infection or systemic inflammatory/autoimmune disease.
- Active malignancy requiring ongoing treatment
- Refusal or inability to provide written informed consent.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of Antegrade Pump Blood Reinfusion Via Crystalloid "Chase" Technique on Postoperative Transfusion Requirements in Adult Cardiac Surgery Patients: A Prospective Observational Study
This prospective observational study aims to evaluate the effect of antegrade pump blood reinfusion using the crystalloid "chase" technique on postoperative transfusion requirements in adult patients undergoing cardiac surgery with cardiopulmonary bypass. At the end of cardiopulmonary bypass, blood remaining within the cardiopulmonary bypass circuit is reinfused antegradely through the arterial line using a crystalloid chase, without collection or storage. Blood remaining within the bypass circuit after surgery represents a valuable source of autologous blood, and its reinfusion may contribute to perioperative blood conservation strategies. Patients receiving antegrade pump blood reinfusion via the chase technique will be compared with those managed without reinfusion, without any intervention by the investigators. The primary outcome is postoperative blood transfusion requirement.
- Conditions
- Coronary Artery Disease
- Being tested
- Antegrade Pump Blood Reinfusion, No Anterograde Pump Blood Reinfusion
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Antegrade Pump Blood ReinfusionProcedure or surgery
Adult patients undergoing cardiac surgery with cardiopulmonary bypass in whom antegrade pump blood reinfusion is performed at the end of bypass using the crystalloid chase technique, as part of routine clinical practice.
No Anterograde Pump Blood ReinfusionOther
Adult patients undergoing cardiac surgery with cardiopulmonary bypass in whom anterograde pump blood reinfusion is not performed at the end of bypass. Standard institutional clinical management is applied.
| Study group | Role | What they receive |
|---|---|---|
| Antegrade Pump Blood Reinfusion (Chase Technique) | Adult patients undergoing cardiac surgery with cardiopulmonary bypass in whom antegrade pump blood reinfusion is performed at the end of bypass using the crystalloid chase technique, as part of routine clinical practice. Receives: Procedure: Antegrade Pump Blood Reinfusion | |
| No Pump Blood Reinfusion | Adult patients undergoing cardiac surgery with cardiopulmonary bypass in whom antegrade pump blood reinfusion is not performed at the end of bypass, and standard clinical management is applied. Receives: Other: No Anterograde Pump Blood Reinfusion |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative Blood Transfusion Requirement
Incidence of allogeneic blood transfusion within the first 24 hours after surgery.
Measured: From the end of surgery to 24 hours postoperatively
Secondary outcomes (1)
Postoperative Drainage Volume
Total postoperative chest drainage volume within the first 24 hours after surgery.
Measured: From the end of surgery to 24 hours postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2026
- Study start23 Feb 2026
- Primary completion11 Aug 2026
- Study completion18 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 130 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kocaeli City Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Zeynep Yasemin Tavşanoğlu, Kocaeli City Hospital
- Investigators
- Zeynep Yasemin Tavsanoglu, MD, Principal investigator, Kocaeli City Hospital, Department of Anesthesiology and Reanimation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07420582
- Sponsor's protocol ID
- KSH_ZYT_1
- Status last verified
- Feb 2026
- First submitted
- 12 Feb 2026
- Last updated
- 21 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Antegrade Pump Blood Reinfusion Via Crystalloid "Chase" Technique on Postoperative Transfusion Requirements in Adult Cardiac Surgery Patients: A Prospective Observational Study
- ClinicalTrials.gov ID
- NCT07420582
- Acronym / sponsor ID
- KSH_ZYT_1
- Conditions
- Coronary Artery Disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 130 participants (actual)
- Lead sponsor
- Kocaeli City HospitalOther government
- Study start
- 23 Feb 2026 (actual)
- Primary completion
- 11 Aug 2026 (actual)
- Study completion
- 18 Aug 2026 (actual)
- First posted
- 19 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective observational study aims to evaluate the effect of antegrade pump blood reinfusion using the crystalloid "chase" technique on postoperative transfusion requirements in adult patients undergoing cardiac surgery with cardiopulmonary bypass. At the end of cardiopulmonary bypass, blood remaining within the cardiopulmonary bypass circuit is reinfused antegradely through the arterial line using a crystalloid chase, without collection or storage. Blood remaining within the bypass circuit after surgery represents a valuable source of autologous blood, and its reinfusion may contribute to perioperative blood conservation strategies. Patients receiving antegrade pump blood reinfusion via the chase technique will be compared with those managed without reinfusion, without any intervention by the investigators. The primary outcome is postoperative blood transfusion requirement.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Antegrade Pump Blood Reinfusion (Chase Technique) | – | Procedure: Antegrade Pump Blood ReinfusionAdult patients undergoing cardiac surgery with cardiopulmonary bypass in whom antegrade pump blood reinfusion is performed at the end of bypass using the crystalloid chase technique, as part of routine clinical practice. |
| No Pump Blood Reinfusion | – | Other: No Anterograde Pump Blood ReinfusionAdult patients undergoing cardiac surgery with cardiopulmonary bypass in whom antegrade pump blood reinfusion is not performed at the end of bypass, and standard clinical management is applied. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population includes adult patients (18-80 years) scheduled for elective, primary isolated coronary artery bypass grafting (CABG) using cardiopulmonary bypass at Kocaeli City Hospital.
Key inclusion criteria (2 listed)
- Age 18 to 80 years
- Patients undergoing elective, isolated coronary artery bypass grafting surgery using cardiopulmonary bypass (on-pump).
Key exclusion criteria (14 listed)
- Emergency or Redo cardiac surgery
- Concomitant cardiac procedures (e.g., valve repair/replacement or aortic surgery).
- Planned or intraoperative conversion to off-pump coronary artery bypass grafting
- Preoperative hematocrit <30% or known inherited/acquired bleeding disorders.
- Preoperative left ventricular ejection fraction <30%.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Antegrade Pump Blood ReinfusionAdult patients undergoing cardiac surgery with cardiopulmonary bypass in whom antegrade pump blood reinfusion is performed at the end of bypass using the crystalloid chase technique, as part of routine clinical practice. | Procedure or surgery | Antegrade Pump Blood Reinfusion (Chase Technique) |
| No Anterograde Pump Blood ReinfusionAdult patients undergoing cardiac surgery with cardiopulmonary bypass in whom anterograde pump blood reinfusion is not performed at the end of bypass. Standard institutional clinical management is applied. | Other | No Pump Blood Reinfusion |
Primary outcome
Postoperative Blood Transfusion Requirement
Time frame: From the end of surgery to 24 hours postoperatively
Incidence of allogeneic blood transfusion within the first 24 hours after surgery.
1 secondary outcome
Postoperative Drainage Volume
Time frame: From the end of surgery to 24 hours postoperatively
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Coronary Artery Disease
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
RecruitingEarly Phase 1
Thiamine Intervention and Coronary Artery Bypass Grafting
Coronary Heart Disease, Coronary Artery Bypass Grafting
RecruitingPhase 4
The Bridging Antiplatelet Therapy With Cangrelor 2 Study
Coronary Arterial Disease (CAD)
Recruiting
Randomized Prospective Trial on the Cost-Effectiveness of Photon-Counting CT Versus Energy-Integrating Detector CT in Suspected Chronic Coronary Syndrome
Computed Tomography Angiography, Coronary Artery Disease
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zeynep Yasemin Tavsanoglu, MD principal investigator
Kocaeli City Hospital, Department of Anesthesiology and Reanimation
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease, run by Kocaeli City Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative Blood Transfusion Requirement (time frame: From the end of surgery to 24 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026; AzTrials last refreshed its copy on 7 Nov 2026.